Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 |
| NCT03108066 | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | completed | Phase 2 | 4 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT01263769 | Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05485896 | Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC | completed | Phase 2 | 23 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | terminated | Phase 2 | 12 | Roberto PiliOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | not yet recruiting | Phase 1 / Phase 2 | 37 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT00554515 | The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma(SELECT) | completed | Phase 2 | 123 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06574412 | Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06523049 | Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy | not yet recruiting | Phase 2 | 67 | Hao ZengOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472895 | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 25, 2024 | clinicaltrials |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma(ERICA) | terminated | Phase 2 | 8 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma(NAPSTER) | unknown | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Bradley A. McGregor, MDOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer | terminated | Phase 2 | 18 | Fundacion OncosurNETWORK | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02782715 | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 3 | University of Wisconsin, MadisonOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | completed | Phase 2 | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019539 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 269 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | withdrawn | Phase 2 | 0 | Sumitomo Pharma America, Inc.INDUSTRY | 0 | Nov 14, 2023 | clinicaltrials |
| NCT04021238 | Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06129955 | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 72 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT00496756 | Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer | terminated | Phase 2 | 14 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT00003102 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 15 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 25 | Mirati Therapeutics Inc.INDUSTRY | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04203901 | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | terminated | Phase 2 | 16 | CoImmuneINDUSTRY | 1 | Oct 2, 2023 | clinicaltrials |
| NCT01517243 | Phase II Study of Alternating Sunitinib and Temsirolimus | completed | Phase 2 | 37 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | withdrawn | Phase 2 | 0 | Bradley A. McGregor, MDOTHER | 0 | Sep 7, 2023 | clinicaltrials |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | active not recruiting | Phase 2 | 46 | Roberto PiliOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT00489710 | Talabostat in Treating Patients With Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 22, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3) | unknown | Phase 2 | 91 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2024source: clinicaltrials